Vanguard Group Inc Arcellx, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,462,096 shares of ACLX stock, worth $223 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,462,096

Previous 2,296,195 7.23%

Holding current value

$223 Million

Previous $127 Million 62.25%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$50.91 - $86.61 $8.45 Million - $14.4 Million	165,901 Added 7.23%	2,462,096 $206 Million
Q2 2024 Aug 13, 2024	BUY	$49.74 - $66.98 $3.35 Million - $4.51 Million	67,339 Added 3.02%	2,296,195 $127 Million
Q1 2024 May 10, 2024	BUY	$51.85 - $73.49 $8.66 Million - $12.3 Million	167,037 Added 8.1%	2,228,856 $155 Million
Q4 2023 Feb 14, 2024	BUY	$31.75 - $57.99 $738,568 - $1.35 Million	23,262 Added 1.14%	2,061,819 $114 Million
Q3 2023 Nov 14, 2023	BUY	$31.51 - $37.4 $1.39 Million - $1.64 Million	43,970 Added 2.2%	2,038,557 $73.1 Million
Q2 2023 Aug 14, 2023	BUY	$27.49 - $46.9 $15.6 Million - $26.6 Million	567,631 Added 39.78%	1,994,587 $63.1 Million
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $1.61 Million - $2.03 Million	-59,898 Reduced 4.03%	1,426,956 $44 Million
Q4 2022 Feb 10, 2023	BUY	$17.18 - $33.0 $4.32 Million - $8.3 Million	251,467 Added 20.36%	1,486,854 $46.1 Million
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $9.47 Million - $12.5 Million	568,296 Added 85.19%	1,235,387 $23.2 Million
Q2 2022 Aug 12, 2022	BUY	$7.21 - $24.43 $1.65 Million - $5.58 Million	228,369 Added 52.05%	667,091 $12.1 Million
Q1 2022 May 13, 2022	BUY	$12.97 - $19.14 $5.69 Million - $8.4 Million	438,722 New	438,722 $6.15 Million

Others Institutions Holding ACLX

# of Institutions

205

Shares Held

44.2M

Call Options Held

2.23M

Put Options Held

907K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.96B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Arcellx, Inc. Transaction History